UBS Group Begins Coverage on MiniMed Group (NASDAQ:MMED)

Research analysts at UBS Group assumed coverage on shares of MiniMed Group (NASDAQ:MMED) in a report released on Tuesday. The brokerage set a “buy” rating and a $25.00 price target on the stock. UBS Group’s price objective points to a potential upside of 41.48% from the stock’s current price.

MMED has been the topic of a number of other research reports. Zacks Research upgraded shares of MiniMed Group to a “hold” rating in a research note on Thursday, April 9th. Bank of America reduced their price objective on shares of MiniMed Group from $27.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, May 18th. BTIG Research started coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $25.00 price objective on the stock. Wells Fargo & Company lowered their target price on shares of MiniMed Group from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, June 4th. Finally, William Blair assumed coverage on MiniMed Group in a research note on Tuesday, March 31st. They issued an “outperform” rating for the company. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, MiniMed Group has a consensus rating of “Moderate Buy” and a consensus price target of $21.62.

MiniMed Group Stock Up 5.0%

Shares of MiniMed Group stock opened at $17.67 on Tuesday. MiniMed Group has a 1-year low of $10.65 and a 1-year high of $20.48. The stock’s fifty day simple moving average is $14.44. The stock has a market cap of $4.96 billion and a PE ratio of -25.99.

MiniMed Group (NASDAQ:MMED) last issued its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The business had revenue of $837.00 million during the quarter. MiniMed Group’s revenue was up 15.6% on a year-over-year basis.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.